Brief: Ocugen Mucosal Vaccine Candidate Ocu500 Selected By Nih/Niaid Project Nextgen

Ocugen

10/10/2023 12:43

Oct 10 (Reuters) - Ocugen Inc  OCGN.O :
    * OCUGEN MUCOSAL VACCINE CANDIDATE OCU500 SELECTED BY
NIH/NIAID
PROJECT NEXTGEN FOR INCLUSION IN CLINICAL TRIALS
    * OCUGEN INC - OCU500 WILL BE TESTED AS BOTH INHALED AND
INTRANASAL VACCINE CANDIDATES
    * OCUGEN INC - CLINICAL TRIALS SCHEDULED TO START IN EARLY
2024
    * OCUGEN INC - CLINICAL TRIALS SCHEDULED TO START IN EARLY
2024
    * OCUGEN INC - UPON COMPLETION OF TRIAL NIAID AND OCUGEN
WILL
ASSESS RESULTS AND DETERMINE NEXT STEPS FOR OCU500

Source text for Eikon:  ID:nGNX9RfzSS 
Further company coverage:  OCGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))